Business Wire

GWI

9.9.2021 06:03:06 CEST | Business Wire | Press release

Share
GWI Revolutionizes Market Research With Brand-new Platform, Democratizing Access to Impactful Audience Insights

GWI, the leading target audience insight company, today launches its brand-new platform that challenges the status quo in market research. The multi-million dollar investment into the new platform provides access to transformational insights, in a meaningful and visual way. Arming employees with one, consistent in-depth view of their global or local audience, the new capabilities power strategic decisions and enable deep understanding of diverse and evolving audiences.

The new platform makes it easy to be an expert on your audience with smart tools that make it simple to explore available datasets. Users are now able to rapidly access deep insights, answering the questions that matter most to make key business decisions based on facts they can trust. It aids businesses to be truly data-driven by putting accessible insights and bespoke dashboards into the hands of everyone across the organization - from decision makers in the C-suite to data analysts, researchers and marketers.

Tom Smith, CEO and Founder at GWI comments, “The new platform enables a new dawn for the future of marketing research, ensuring it is suited for today's environment which consists of rapid change of pace for business and consumers. Our data shows that 72%* of professionals globally agree that being able to adapt quickly is critical to their company’s long term success. Yet, the traditional market research industry has utterly failed the needs of its customers in today's global marketplace - a world where almost 5 billion people are permanently connected online. Uncovering really transformative insight isn’t easy, nor is it always ‘on time’. Traditional research often takes several months, and can be delayed throughout the process. Despite heavy investment, the insights can therefore quickly become outdated, whilst putting market research out of reach for nearly every single organisation.

“With our new platform combined with our tried and tested methodology, you can secure insights and answers in an instant versus a drawn out process, at a fraction of the traditional market research cost. At the same time, you can ensure organizational alignment, meaning everyone is working from a single source of truth - to tell the same story, inform the decisions that matter and deliver impactful results.”

The intuitive new platform provides access to the world’s largest harmonized ongoing study on digital consumers, representing 2 billion people globally. Users of the flagship survey, GWI Core, alone can gather insights from over 40,000 data points, from over 800,000 interviews. The new platform will foster smarter business decisions and outcomes using hyper-targeted insights into any consumer group, in local and global markets.

To learn more about the new platform including new features and capabilities or to book a demo please visit here .

ENDS

About GWI

GWI is the leading supplier of target audience insight to the global marketing industry.

Trusted by the world’s biggest brands, media organizations, and agencies on a daily basis to get closer to their audiences, the company’s flagship survey represents over 2 billion people globally. Using the subscription-based platform, clients like Twitter, Google, Spotify, WPP, IPG, and Omnicom Group gather in-depth insights into behaviors, attitudes, and interests in seconds through a combination of survey data and analytics.

Among a range of leading data products available alongside its flagship survey are:

  • GWI USA is a deep dive into the habits, behaviors and attitudes of 240m internet users in the USA.
  • GWI Gaming delves into the actions and attitudes of gamers across 15 markets.
  • GWI Sports investigates sports fandom and participation across 15 markets.
  • GWI Kids gets to the heart of how kids actually think, so you can be sure to kid-proof your ideas and concepts from here on.
  • GWI Work gives a detailed view of the lives of business professionals across 10 markets.
  • GWI Zeitgeist, included with our core survey, is fielded monthly and zeroes in on the stuff that matters. It’s topical, timely, and relevant.

Those looking for even more bespoke research solutions can enrich GWI data with a range of services like hyper-targeted custom surveys, brand trackers, and recontact studies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release

‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub

Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release

New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki

Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release

90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release

For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye